Maze Therapeutics Inc (MAZE)

Sep 25, 2026

Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now? - Yahoo Finance

Sep 25, 2026

Sep 23, 2026

Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - Yahoo Finance Australia

Sep 23, 2026

Sep 23, 2026

Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 23, 2026

Sep 23, 2026

Maze Therapeutics Price Target Maintained With a $46.00/Share by BTIG - Moomoo

Sep 23, 2026

Sep 23, 2026

Maze Therapeutics Initiated at Buy by Citigroup - Moomoo

Sep 23, 2026

Sep 23, 2026

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga

Sep 23, 2026

Sep 23, 2026

A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $46 to $110 - Moomoo

Sep 23, 2026

Sep 23, 2026

Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage - Yahoo Finance

Sep 23, 2026

Sep 23, 2026

Why is Maze Therapeutics stock climbing today? By Investing.com - Investing.com Canada

Sep 23, 2026

Sep 23, 2026

Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target - Yahoo Finance

Sep 23, 2026

Sep 23, 2026

BTIG Initiates Maze Therapeutics at Buy With $50 Price Target - Yahoo Finance

Sep 23, 2026

Sep 22, 2026

The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily

Sep 22, 2026

Sep 22, 2026

Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's

Sep 22, 2026

Sep 22, 2026

Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $64 - Moomoo

Sep 22, 2026

Sep 22, 2026

BTIG reiterates Buy rating on Maze Therapeutics, $46 price target - TradingView

Sep 22, 2026

Sep 18, 2026

Maze Therapeutics stock hits 52-week low at 22.44 USD By Investing.com - Investing.com India

Sep 18, 2026

Sep 18, 2026

Maze Therapeutics stock hits 52-week low at 22.44 USD - Investing.com

Sep 18, 2026

Sep 18, 2026

Maze Therapeutics, Inc. (MAZE) Stock Analysis: A 166.83% Potential Upside in the Biotech Arena - DirectorsTalk Interviews

Sep 18, 2026

Sep 16, 2026

Maze Therapeutics (MAZE) Slips 1.30% to $23.91 as Shares Drift Toward Key SupportRunaway Gap - careplusvn.com

Sep 16, 2026

Sep 15, 2026

Maze Therapeutics at H.C. Wainwright conference: pipeline nears key tests By Investing.com - Investing.com Canada

Sep 15, 2026

Sep 11, 2026

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Motley Fool

Sep 11, 2026

Sep 10, 2026

Maze Therapeutics at Citi summit: early data, bigger tests ahead By Investing.com - Investing.com South Africa

Sep 10, 2026

Sep 10, 2026

Wells Fargo Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $55 - Moomoo

Sep 10, 2026

Sep 09, 2026

Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Australia

Sep 09, 2026

Sep 09, 2026

Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Nigeria

Sep 09, 2026

Sep 09, 2026

Maze Therapeutics (MAZE) Institutional Ownership 2026 - MarketBeat

Sep 09, 2026

Sep 08, 2026

Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com India

Sep 08, 2026

Sep 08, 2026

Maze Therapeutics (MAZE) R&D chief exits direct stake - Stock Titan

Sep 08, 2026

Sep 08, 2026

Maze Therapeutics CSBO Atul Dandekar Disposes of 6,434 Shares at $25.81-$27.12 (NASDAQ: MAZE) - Kalkine Media

Sep 08, 2026

Sep 06, 2026

Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st

Sep 06, 2026

Sep 06, 2026

Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga

Sep 06, 2026

Sep 04, 2026

MAZE News | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill

Sep 04, 2026

Sep 04, 2026

Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026 - Kalkine Media

Sep 04, 2026

Sep 04, 2026

Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding - Kalkine Media

Sep 04, 2026

Sep 04, 2026

Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - Stock Titan

Sep 04, 2026

Sep 04, 2026

Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593K - TradingView

Sep 04, 2026

Sep 04, 2026

Maze Therapeutics (MAZE) legal chief sells stock for taxes - Stock Titan

Sep 04, 2026

Sep 04, 2026

Insider at Maze Therapeutics (MAZE) sells shares to cover taxes - Stock Titan

Sep 04, 2026

Sep 04, 2026

Maze Therapeutics (MAZE) CEO sells shares to cover taxes - Stock Titan

Sep 04, 2026

Sep 04, 2026

Maze Therapeutics (MAZE) R&D chief sells shares to cover RSU taxes - Stock Titan

Sep 04, 2026

Sep 04, 2026

Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine

Sep 04, 2026

Sep 03, 2026

Maze Therapeutics Officer Courtney Phillips Reports RSU Vesting and Stock Settlement - Kalkine Media

Sep 03, 2026

Sep 03, 2026

Maze Therapeutics CEO Jason V Coloma Reports RSU Vesting and Trust Share Sales in Form 4 Filing - Kalkine Media

Sep 03, 2026

Sep 03, 2026

RSU vesting gives Maze Therapeutics (MAZE) exec 12,500 shares - Stock Titan

Sep 03, 2026

Sep 03, 2026

Maze Therapeutics (MAZE) CEO gets 50K shares, trims stake via trust sales - Stock Titan

Sep 03, 2026

Sep 03, 2026

Rule-based stock plan leads Maze Therapeutics (MAZE) exec to sell shares and log 20,000 RSUs - stocktitan.net

Sep 03, 2026

Sep 03, 2026

Maze Therapeutics (MAZE) legal chief gets 11,000 shares - Stock Titan

Sep 03, 2026

Sep 02, 2026

Officer plans to sell up to $623K in Maze Therapeutics (MAZE) stock from vested RSUs - Stock Titan

Sep 02, 2026

Sep 02, 2026

Maze Therapeutics to Participate in Three Upcoming Investor Conferences - markets.businessinsider.com

Sep 02, 2026

Sep 02, 2026

Maze Therapeutics (MAZE) executive plans new stock sale after recent trades - Stock Titan

Sep 02, 2026